Top in hem/onc: New breast cancer treatment, CAR T-cell therapy for lymphoma

Last week, the FDA approved margetuximab-cmkb for the treatment of patients with metastatic HER2-positive breast cancer. It was the top story in hematology/oncology.

Another top story was about the role of chimeric antigen receptor T-cell therapy as a first-line option for patients with high-risk large B-cell lymphoma.

Read these and more top stories in hematology/oncology below:

FDA approves Margenza for metastatic HER2-positive breast cancer

The FDA approved margetuximab-cmkb (Margenza, MacroGenics) for use in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer, according to a press release from the agent’s manufacturer. Read more.

CAR-T effective as first-line therapy for high-risk large B-cell lymphoma

First-line therapy with axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) induced an objective response in 85% of patients with high-risk large B-cell lymphoma, according to phase 2 study results presented at the virtual ASH Annual Meeting and Exposition. Read more.

Elevenses with Mark Lewis, MD: Rare Cancers, On Becoming an Oncologist, and Hope

Mark A. Lewis, MD, a medical oncologist specializing in cancers of the gastrointestinal tract and accessory organs, talks about his path to becoming a GI oncologist and living with multiple endocrine neoplasia type 1. Read more.

FDA approves Orgovyx, first oral hormone therapy for advanced prostate cancer

The FDA approved relugolix (Orgovyx, Myovant Sciences) for the treatment of men with advanced prostate cancer. Read more.

FDA approves Riabni, third biosimilar to Rituxan

The FDA approved rituximab-arrx (Riabni, Amgen) for multiple indications. Read more.